STOCKHOLM, April 26, 2019 /PRNewswire/ -- The Annual
General Meeting (AGM) of Immunovia AB (publ), corporate identity
number 556730-4299 was held at Gamla Gästmatsalen in Medicon
Village, Scheelevägen 2, Lund,
Sweden on April 26 2019. A
summary of the Meeting's resolutions follows:
Appropriation of the company's profit and loss
The Meeting resolved that the funds at its disposal of
SEK 442,629,518 should be carried
forward.
Directors' and audit fees
The Meeting resolved that Board members should be compensated
with SEK 150,000 for Directors and
SEK 400,000 for the Chairman of the
Board. The Chairman of the Audit Committee and Remuneration
Committee were compensated with SEK
40,000, and other members of these Committees were
compensated with SEK 20,000. Travel
expenses will be reimbursed in accordance with the company's
policy. The Meeting also resolved that the auditors should be paid
according to approved account.
Election of the Board of Directors, Chairman of the Board and
auditors
The Meeting resolved to re-elect the Directors Carl Borrebaeck, Ann-Christine Sundell, Hans Johansson, Mimmi
Ekberg and Christofer Sjögren as Directors, and elect Carl
Borrebaeck as Chairman of the Board. The current board member Åsa
Hedin has declined re-election. The Meeting elected authorized
auditor Mats-Åke Andersson (who was previously the Company's
Auditor in Charge) to be the company's auditor, with authorized
public accountant Martin Gustafsson
as deputy auditor.
Guidelines for remunerating senior executives
The Meeting resolved to adopt guidelines for remunerating senior
executives based on a proposal that the Board produced after
recommendation from the Remuneration Committee.
Resolution to authorize the Board to take decisions on new
share issues
The Meeting resolved to authorize the Board to decide on the new
issue of an aggregate maximum number of shares that would mean a
maximum increase of the share capital of twenty (20) percent based
on the aggregate share capital of the company at the time of the
AGM 2019, in accordance with, or departing from, shareholders'
preferential rights, and with or without a decision on contribution
in kind.
Resolution on incentive programm for key individuals
The Meeting approved the issue of a maximum of 191,000 share
warrants to key individuals of the company, waiving shareholders'
preferential rights, and authorised the Board to introduce an
alternative cash-based incentive program for key individuals in
countries where the allocation of shares is not appropriate.
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
Immunovia AB (publ)
The Board of Directors
Questions should be addressed to:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia---report-from-agm,c2798432
The following files are available for download:
https://mb.cision.com/Main/13121/2798432/1033169.pdf
|
Press
Release
|